Featured Firms
Presented by BigVoodoo
A group of cutting-edge drugs known as biologics has generated billions in sales for brand-name drug makers. But generic drug makers are looking to crack the market. And that has unleashed a lobbying and legal battle targeting members of Congress and the FDA. William Schultz, who represents the Generic Pharmaceutical Association, says the agency needs to set up a regulatory system for generic biologics.
July 12, 2004 at 12:00 AM
1 minute read
The original version of this story was published on Legal Times
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS